If everything goes right around 2026, but it will be for limited number of patients.
Update From The God Himself - Dr. Takashi Tsuji
- Thread starter kingjohn
- Start date
- Reaction score
- 179
the question is, how will they make sure that the cloned dermal papilla cells do not die in the new aptotic environment in the frontal scalp. when doing a hair transplant the DPs from the back are extracted with the entire follicle so also with the mesenchyme dermal stem cells and progenitors for the dermal papilla cells that all have seemingly a methylated(down regulated) androgen receptor gene. however, in environment of high DHT like the frontal scalp even a lower AR expression can lead to minaturization(e.g hair transplant goes to sh*t without finasteride for young men even the transplanted donor hair will thin in the high androgen front) and additionally lots of death signals like tgfb and IL-6 in this area.
so I wonder, if they extract the dermal papilla cells and culture them to form an organoid, the dermal sheath must also arise from this and it must have the same properties as the occipital follicles otherwise you need an anti androgen. I can see tsuij doing this because they actually culture dermal papilla cells, however for stemson I dont know what the expression profile of their DP cells is like.
I guess you could edit the genes in vitro however you like and probably push the cells to not express certain genes like AR or SDR5A1/2/3.
thats the only way you can make them androgen resistant. however I wonder if that would bring additional hurdles as this could classify as gene therapy? not just cloning of an organ but making epigenetic changes to it? it seems its not really clear regulatory wise how this would be judged
I think the fact that the cloned hairs in mice from human mesenchyme showed proper cycling suggests that they can also regenerate the dermal sheath. as the dermal papilla cells regenerate from their progenitors in the dermal sheath, if the DS was damaged, the hair would disintegrate after a few cycles because DP cells themselves have been observed to not really proliferate and rely on the stem cell pool from the DS). tsujis approach the AR sensitivity could then be straight forward, if the AR expression during culture does not change it should be as resistant as transplanted hairs. these also thin over time but much slower
so I wonder, if they extract the dermal papilla cells and culture them to form an organoid, the dermal sheath must also arise from this and it must have the same properties as the occipital follicles otherwise you need an anti androgen. I can see tsuij doing this because they actually culture dermal papilla cells, however for stemson I dont know what the expression profile of their DP cells is like.
I guess you could edit the genes in vitro however you like and probably push the cells to not express certain genes like AR or SDR5A1/2/3.
thats the only way you can make them androgen resistant. however I wonder if that would bring additional hurdles as this could classify as gene therapy? not just cloning of an organ but making epigenetic changes to it? it seems its not really clear regulatory wise how this would be judged
I think the fact that the cloned hairs in mice from human mesenchyme showed proper cycling suggests that they can also regenerate the dermal sheath. as the dermal papilla cells regenerate from their progenitors in the dermal sheath, if the DS was damaged, the hair would disintegrate after a few cycles because DP cells themselves have been observed to not really proliferate and rely on the stem cell pool from the DS). tsujis approach the AR sensitivity could then be straight forward, if the AR expression during culture does not change it should be as resistant as transplanted hairs. these also thin over time but much slower
Last edited:
- Reaction score
- 179
what's your achievement?
- Reaction score
- 892
His achievement is an ability to predict future events based on current state + previous industry failures
- Reaction score
- 179
yes the future always follows from the past, progress is never made, things never converge to improvementHis achievement is an ability to predict future events based on current state + previous industry failures
Doesn’t have to do with this but check out the updates on Verteporfin, as typical we couldn’t raise enough to keep funding hair transplants to test the effectiveness of Verteporfin and a user donated almost 15k himself to keep it going. Verteporfin could be used this year, unfortunately Tsuji won’t be available for years if ever. Check it out guys Verteporfin.org
- Reaction score
- 179
verteporfin is okay when you either are already of old age and want to do a transplant and might need a little more grafts, young guys who can use and tolerate maintenance drugs like finasteride. however for young guys who have extensive baldness verteporfin won't be the solution at all, there is no guarantee that you will respond to the drug at all and you have to do a transplant first to find out. however since most people here are not candidates at all(transplants are really a meme at this point and done way to often) or cant tolerate maintenance drugs, this won't work. you need somewhat of a guarantee that you will grow enough hair back in the donor area where it allows you to potentially cover a NW7 area. this is the same requirement that you'd have for hair cloning with the difference that cloning does not when it goes wrong, deplete your donor area.
I think if someone will be successful in the hair cloning area it won't likely be tsuji because his method is apparently not very scaleable. so much so that other researchers like Junji Fukuda have commented on it being scientifically smart but not scaleable for large scale production.
I think if someone makes it its either stemson because they bet on high scalability from the start or Fukuda. Stemson recently hired someone who usually takes care of clinical trials so maybe the are getting ahead, however the history and there I will agree with Kiwi tells us that its often not a good idea to be optimistic about any of this stuff.
I think if someone will be successful in the hair cloning area it won't likely be tsuji because his method is apparently not very scaleable. so much so that other researchers like Junji Fukuda have commented on it being scientifically smart but not scaleable for large scale production.
I think if someone makes it its either stemson because they bet on high scalability from the start or Fukuda. Stemson recently hired someone who usually takes care of clinical trials so maybe the are getting ahead, however the history and there I will agree with Kiwi tells us that its often not a good idea to be optimistic about any of this stuff.
Disagree with the young guys with Verteporfin. The whole point with Barghouthis trials right now is to find a consistent method that brings out the highest percentage of improvement, therefore creating a consistent method. Another thing you could do is go from a Norwood 7 to a 4 then check your donor again and see if you can lower, 4 to 2 then lower if possible. Not amazing but way way better than what we currently have now.
- Reaction score
- 179
I just dont see it happening. the risk is too high. also you dont really know how the donor grows back, the quality of those hair, if you can harvest them again for example. if you cant tolerate maintenance drugs then you need more donor what if its then depleted. with cloning you have infinite donor and you dont need to get massive scars on your head that also dont heal completely. verteporfin im sure can help with scar healing, however its very unlikely it can completely amoreliate it because then it would be the holy grail for other fields in dermatology and rn it doesnt seems to have reached that interest or status
OrganTech got funding and partnership from Kobayashi Pharmaceutical to start clinical trials by the beginning of 2024. Not only about hair cloning, but tooth regeneration as well.
Kobayashi Pharmaceutical is planning to expand their company in regenetative medecine and AI technology in future.
Kobayashi Pharmaceutical is planning to expand their company in regenetative medecine and AI technology in future.
- Reaction score
- 108
Kobayashi pharmaceutical is the worst name for a pharmaceutical. Anyone who watches star trek knows about the Kobayashi maru. A simulation of a space mission designed to have you fail. Only captain kirk beat it by altering the conditions of the simulation to make it winnable.
So unless William Shatner is a key contributor, this company is doomed.
The fact that Tsuji couldn't get funding easily makes me suspicious he a.) hasn't solved certain key issues related to the treatment, b.) can't prove it will be as effective as everyone thinks or c.) they expect some other operational issues/contstraints going to market. A new treatment like this would be a goldmine and $500 million could be recouped relatively quickly, especially from different backers.
New interview with Miho Ogawa, representative director in OrganTech.
rec.weekly-economist.com
REC [ 世界初・日本発の器官再生医療の事業化を進めるパイオニア ] ｜株式会社オーガンテック”
RECは様々な分野で活躍されている経営者の“今”を記録するインタビューメディアです。今回は株式会社オーガンテック 小川美帆さんのカットをご紹介します。”
Miho Ogawa and Takashi Kondo, representative directors in OrganTech
challenger.newsweekjapan.jp
Received the award in the SDGs category of the "Economist Future Award 2023" held on June 25, 2023 (Sponsor: Economist Future Award 2023 Executive Committee/Sponsor: Mainichi Shimbun Publishing Co., Ltd.)
CHALLENGING INNOVATOR｜GUEST
一見誰もが無謀と感じる挑戦こそが、世の中に新しい価値をもたらす。そしてそのチャンスは、誰にでも平等にある。今回のCHALLENGING INNOVATORは氏です。
challenger.newsweekjapan.jp
Received the award in the SDGs category of the "Economist Future Award 2023" held on June 25, 2023 (Sponsor: Economist Future Award 2023 Executive Committee/Sponsor: Mainichi Shimbun Publishing Co., Ltd.)
CEO Takashi Kondo gave video presention on VentureTV. Somebody knows japanese to translate little bit?
Sanchez1234
Experienced Member
- Reaction score
- 311
TSUJI back from the dead
FT new interview (25 oct:
folliclethought.com
Summary:
- New CEO, specializes in fund raising
- “Regarding the hair regeneration business, we are preparing documents for clinical research, and we plan to transplant regenerated hair follicle primordia into humans as early as the second quarter of 2024”
- “We are planning to go public and raise funds in the stock market to further our research and development efforts. After analyzing, we believe that NASDAQ is the most suitable stock exchange for this purpose, and we have currently started preparations for the listing.”
- “continuing research to further enhance the hair growth rate and plan to sequentially perform primordia transplants into humans using new technology”
Interesting developments
FT new interview (25 oct
:
OrganTech Hair Cloning Interview 2023 - Follicle Thought
Follicle Thought is pleased to share an exclusive interview with the CEO of OrganTech as we draw closer to 2024. OrganTech Inc. Resurgence Prior to the year 2020, one researcher’s name was held synonymously with the topic of hair cloning by online hair-seeking communities – Dr. Takashi Tsuji...
folliclethought.com
Summary:
- New CEO, specializes in fund raising
- “Regarding the hair regeneration business, we are preparing documents for clinical research, and we plan to transplant regenerated hair follicle primordia into humans as early as the second quarter of 2024”
- “We are planning to go public and raise funds in the stock market to further our research and development efforts. After analyzing, we believe that NASDAQ is the most suitable stock exchange for this purpose, and we have currently started preparations for the listing.”
- “continuing research to further enhance the hair growth rate and plan to sequentially perform primordia transplants into humans using new technology”
Interesting developments
OrganTech got award by Startup City for Top Biotech Startup for 2023 in APAC region.
www.startupcity.com
OrganTech | Top Biotech Startup in APAC-2023
OrganTech has been recognized as Top 10 Biotech Startups in APAC - 2023 by Startup City Magazine. OrganTech Inc., a leading Japanese biotechnology company, brings Japan's and...
www.startupcity.com